Health Condition 1: F59- Unspecified behavioral syndromes associated with physiological disturbances and physical factors
Conditions
Interventions
Intervention1: Tab. Olanzapine 5mg and tab. Melatonin 9mg and Haloparidol 2.5 mg orally: Within 5 hours of diagnosis of delirium.
Control Intervention1: Tab. Melatonin and Tab. Olanzapine and tab. hal
Sponsors
Self Sponsored
Eligibility
Inclusion criteria
Inclusion criteria: 1) Written and informed consent from patients 2) Critically ill patients Age >18 or 3) All patients having delirium assessed through CAM-ICU scale were considered eligible for the study 4) Patients who are verbally responsive, and not having demenî??a wereincluded in the study. 5) Diagnosed within five hours of onset of delirium
Exclusion criteria
Exclusion criteria: 1.If they had less than 5 days of ICU stay 2.Sensitivity reaction to the melatonin and olanzapine supplement. 3.Pregnancy 4.Previous history of seizure or active seizure 5.Unable to assess for delirium 6.History of severe cognitive or neurodegenerative disease 7.Unable to communicate in English or Hindi 8.Absolute contraindication to enteral nutrition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare melatonin and olanzapine for treating delirium in critically ill patients in terms of following parameters: - 1)Severity of delirium measured with the Memorial Delirium Assessment Scale (MDAS) 2)delirium durationTimepoint: Every 24 to 48 hours till total duration in ICU stay. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To observe the length of stay in ICU 2. To observe adverse effects of melatonin and olanzapine 3. pattern of symptom improvement with treatment of delirium Timepoint: Every 24 to 48 hours till total duration in ICU stay. | — |
Countries
India
Contacts
Public ContactPriyamvada Gupta
Mahatma Gandhi University of Medical Science and Technology
Outcome results
None listed